LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.

Shanghai’s Elpiscience Biopharma has formed a $1.7 billion collaboration with Japan’s Astellas Pharma to develop a novel bispecific macrophage engager, ES019, along with an unspecified program. Initially, Elpiscience will receive up to $37 million.

LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of a LianBio holding.

Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its OrbiMed Asia V fund.

Other funding deals for drug discovery, R&D, gene editing.